Abstract
Introduction Respiratory Syncytial Virus (RSV) infection is a major cause of acute respiratory hospitalizations in young children and older adults. In early 2020 most countries implemented non-pharmaceutical interventions (NPIs) to slow the spread of SARS-CoV-2. COVID-19 NPIs disrupted the transmission of RSV on a global scale, and many locations did not experience widespread re-circulation until late 2020 or 2021. Here, we use a mechanistic transmission model informed by cellphone mobility data to determine which aspects of population behavior had the greatest influence on post-pandemic RSV rebound in Seattle, Washington.
Methods We used aggregated mobile device location data to characterize within-city mixing, visitor in-flows, and foot traffic to points of interest in Seattle. We fit an age-structured epidemiological model to data on weekly RSV hospitalizations, allowing for reductions in transmission due to declines in mobility during the pandemic. We compared model fits to observed data to assess which mobility behaviors best capture RSV dynamics during the first two post-pandemic waves in Seattle.
Results In Seattle, COVID-19 NPIs perturbed RSV seasonality from 2020 to 2022. Seattle experienced a small out-of-season outbreak in Summer 2021 and an atypically large and early wave in Fall 2022. RSV transmission models incorporating mobility network connectivity (measured as the average shortest path length between Seattle neighborhoods) or the inflow of visitors from outside of Seattle best captured the timing and magnitude of the first two post-pandemic waves. Models including foot traffic to schools or child daycares or within-neighborhood movement produced poor fits to observed data.
Conclusions Our results suggest that case importations from other regions and local spread between neighborhoods had the greatest influence on the timing of RSV reemergence in Seattle. These findings contribute to the understanding of behavioral factors underlying RSV epidemic spread and can inform the timing of preventative measures, such as the administration of immunoprophylaxis.
Competing Interest Statement
C.L.H reports receiving personal fees from Sanofi outside the submitted work. C.V. reports receiving honoraria from Elsevier outside the submitted work. No other disclosures were reported.
Funding Statement
This work is the output of the Complexity72h workshop, held at the Universidad Carlos III de Madrid in Leganés, Spain, 24-28 June 2024 (https://www.complexity72h.com). A.C.P. acknowledges support from the Fogarty International Center at the U.S. National Institutes of Health to carry out this project. This study modifies a transmission model for RSV originally developed by C.L.H. in collaboration with Public Health - Seattle & King County for an initiative supported by the U.S. Council of State and Territorial Epidemiologists and U.S. Centers for Disease Control and Prevention: "Development of forecast, analytic, and visualization tools to improve outbreak response and support public health decision making."
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was determined to be non-human subjects research by the University of Washington Institutional Review Board (#00017840). The human cellphone mobility data are aggregated and anonymous and were freely available to academic researchers prior to the start of this study; thus, these data do not constitute human subjects research. There is no individual-level linkage between the hospitalization and mobility datasets. Individual-level linkage between these two datasets is not possible, given that both datasets are aggregated and anonymous/de-identified.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw hospitalization data for King County, WA are not publicly available but the final dataset of hospitalizations used in this study can be accessed at https://github.com/chelsea-hansen/RSV-Interventions. Aggregated mobility data for King County can be accessed at https://github.com/aperofsky/seattle_mobility_rt. The SafeGraph Weekly Patterns dataset is available to academics for non-commercial use through an institutional university subscription or individual subscription to Dewey (https://www.deweydata.io/). The data access agreement with Dewey does not permit sharing of the raw data.
